<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00254982</url>
  </required_header>
  <id_info>
    <org_study_id>P04320</org_study_id>
    <secondary_id>2005-001243-28</secondary_id>
    <nct_id>NCT00254982</nct_id>
  </id_info>
  <brief_title>Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)</brief_title>
  <official_title>An Open-Label Study to Determine Equivalence in Efficacy, Organ Safety and Systemic Tolerability Between Infliximab in GROUP I (&quot;High Need&quot;) and GROUP II (&quot;Low Need&quot;) Patients Suffering From Chronic Plaque Psoriasis (Psoriasis Vulgaris)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Essex Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, parallel-group comparison study of the efficacy, safety,
      and tolerability of infliximab therapy in adult patients suffering from chronic plaque
      psoriasis (psoriasis vulgaris). Patients will be assigned to GROUP I (&quot;high need&quot;) or GROUP
      II (&quot;low-need&quot;) by the investigator according to their previous psoriasis treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants Achieving a Greater Than or Equal to 75% Improvement in Psoriasis Area and Severity Index (PASI75) Score</measure>
    <time_frame>Baseline and Week 22</time_frame>
    <description>PASI75 response is defined as participants who achieved at least a 75% improvement in PASI score from Baseline to Week 22. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their responses to therapy. The PASI produces a numeric score that can range from 0 to 72 (the higher the number, the worse the disease).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">593</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Group 1 (high-need)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult participants with moderate to severe plaque psoriasis who were either not controlled by, or were intolerant to or had contraindications to at least two currently available systemic therapies (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (low-need)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult participants with moderate to severe plaque psoriasis who had undergone pretreatment with no more than one currently available systemic therapy (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.</description>
    <arm_group_label>Group 1 (high-need)</arm_group_label>
    <arm_group_label>Group II (low-need)</arm_group_label>
    <other_name>Remicade</other_name>
    <other_name>SCH 215596</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent by the patient for study participation, prior to protocol
             specific procedures.

          -  Patients who are 18 years of age or older at time of enrollment, may be male or female
             and of any race.

          -  Diagnosis of plaque-type psoriasis (psoriasis vulgaris) at least 6 months prior to
             screening.

          -  Plaque-type psoriasis covering at least 10% of total body surface area.

          -  Psoriasis Area and Severity Index (PASI)-Score of 12 or greater.

          -  GROUP I (&quot;high need&quot;) patients: adult patients with moderate to severe plaque
             psoriasis who are either not controlled by, or are intolerant to or have
             contraindications to at least two currently available systemic therapies (e.g.
             photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters,
             efalizumab, etanercept). GROUP II (&quot;low need&quot;) patients: adult patients with moderate
             to severe plaque psoriasis who have undergone pre-treatment with no more than one
             currently available systemic therapy (e.g. photochemotherapy, cyclosporine,
             methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept). A patient
             showing contraindications towards two systemic treatments, who has never been
             pretreated with a systemic therapy will be assigned to GROUP II (&quot;low need&quot;).

          -  Patients must have had a chest x-ray (preferably posteroanterior and lateral) within 3
             months prior to first infusion with no evidence of malignancy, infection (e.g.
             tuberculosis) or fibrosis.

          -  Laboratory test results: liver enzymes (aspartate aminotransferase (AST), alanine
             aminotransferase (ALT), gamma glutamyl transferase (GGT) and alkaline phosphatase)
             must be within 1.5 times the upper limit of normal range (ULN), total bilirubin &lt;=1.0
             ULN, serum creatinine &lt;1.5 mg/dL (must be available at Baseline).

          -  Patients must agree to avoid prolonged sun exposure or other ultraviolet light sources
             during the study.

          -  Women of child-bearing potential must agree to use a medically accepted method of
             contraception prior to screening, while receiving protocol-specified medication, and
             for six months after stopping the medication. Acceptable methods of contraception
             include abstinence, condoms (male or female) with or without a spermicidal agent,
             diaphragm or cervical cap with spermicide, medically prescribed intrauterine device
             (IUD), oral or injectable hormonal contraceptive, and surgical sterilization (e.g.
             hysterectomy or tubal ligation).

          -  Women of child-bearing potential must have a negative serum pregnancy test (beta-human
             chorionic gonadotropin [hCG]) at Screening (must be available at Baseline).

          -  Baseline PASI-Score of 12 or greater.

        Exclusion Criteria:

          -  Patients suffering from active or latent tuberculosis. Prior to the start of treatment
             with infliximab tuberculosis needs to be excluded following the recommendations
             published by the German Paul Ehrlich Institute.

          -  Patients who have had or have a serious infection (e.g. abscess, pneumonia or
             pyelonephritis) or who have been hospitalized or received treatment with intravenous
             antibiotics during the previous 2 months.

          -  Patients who are known to be infected with human immunodeficiency virus, hepatitis B
             or C virus, prior or current opportunistic infections (within the last six months,
             Herpes zoster within the last 2 months).

          -  Patients suffering from congestive heart failure including medically controlled
             asymptomatic patients.

          -  History of demyelinating disease or symptoms suggestive of multiple sclerosis or optic
             neuritis.

          -  Patients who have current signs and symptoms or history of systemic lupus
             erythematosus.

          -  Patients suffering from non-plaque psoriasis, e.g. erythrodermic, guttate or pustular
             forms. The presence of psoriasis-arthritis is no exclusion criterion.

          -  Patients suffering from current drug induced psoriasis (e.g. a new onset of psoriasis
             or an exacerbation of psoriasis from beta-blockers or calcium-channel-blockers). If
             the patient takes one of those substances on a regular basis, it should be on a stable
             dose for at least three weeks prior to Baseline.

          -  Patients suffering from severe, progressive or uncontrolled renal, hepatic,
             hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, cerebral
             or psychiatric diseases, that, in the opinion of the investigator, would interfere
             with the study evaluations or safe or optimal participation in the study.

          -  Any known malignancy during the last five years (except basal cell carcinoma), any
             history of lymphoproliferative disease.

          -  Patients who have received any systemic psoriasis therapy (e.g. immunosuppressant) or
             lithium within 28 days or baseline visit.

          -  Patients pretreated with etanercept or efalizumab within 28 days of Baseline.

          -  Patients previously treated with infliximab.

          -  Patients who have used topical treatments that could affect PASI evaluation (e.g.
             corticosteroids, anthralin, topical vitamin D derivates) within 2 weeks of baseline
             visit, except special areas like head or hands.

          -  Patients who have used any investigational drug within 3 months of Baseline.

          -  Patients with allergy/sensitivity to study drug or its excipients.

          -  Women who are breast-feeding, pregnant, or intend to become pregnant.

          -  Patients with any clinically significant condition or situation, other than the
             condition being studied.

          -  Patients who are participating in any other clinical study.

          -  Patients who are part of the staff personnel directly involved with this study.

          -  Patients who are a family member of the investigational study staff.

          -  Patients who have used any investigational drug within 3 months before Baseline.

          -  Patients who have received any systemic psoriasis therapy (e.g. immunosuppressants) or
             lithium within 28 days of baseline visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2005</study_first_submitted>
  <study_first_submitted_qc>November 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2005</study_first_posted>
  <results_first_submitted>May 27, 2010</results_first_submitted>
  <results_first_submitted_qc>May 27, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 5, 2010</results_first_posted>
  <last_update_submitted>October 9, 2015</last_update_submitted>
  <last_update_submitted_qc>October 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 (High-need)</title>
          <description>Adult participants with moderate to severe plaque psoriasis who were either not controlled by, or were intolerant to or had contraindications to at least two currently available systemic therapies (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept). Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.</description>
        </group>
        <group group_id="P2">
          <title>Group II (Low-need)</title>
          <description>Adult participants with moderate to severe plaque psoriasis who had undergone pretreatment with no more than one currently available systemic therapy (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept). Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="297"/>
                <participants group_id="P2" count="296"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="261"/>
                <participants group_id="P2" count="265"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion/exclusion criteria violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Diagnosis of Tuberculosis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Malignancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Opportunistic infection</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal liver function tests</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 (High-need)</title>
          <description>Adult participants with moderate to severe plaque psoriasis who were either not controlled by, or were intolerant to or had contraindications to at least two currently available systemic therapies (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept). Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.</description>
        </group>
        <group group_id="B2">
          <title>Group II (Low-need)</title>
          <description>Adult participants with moderate to severe plaque psoriasis who had undergone pretreatment with no more than one currently available systemic therapy (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept). Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="297"/>
            <count group_id="B2" value="296"/>
            <count group_id="B3" value="593"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 83 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="297"/>
                    <measurement group_id="B2" value="296"/>
                    <measurement group_id="B3" value="593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;83 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Participants Achieving a Greater Than or Equal to 75% Improvement in Psoriasis Area and Severity Index (PASI75) Score</title>
        <description>PASI75 response is defined as participants who achieved at least a 75% improvement in PASI score from Baseline to Week 22. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their responses to therapy. The PASI produces a numeric score that can range from 0 to 72 (the higher the number, the worse the disease).</description>
        <time_frame>Baseline and Week 22</time_frame>
        <population>Per Protocol Population - All participants in the intent to treat population who completed the study without major protocol violations. For missing data, the last observation carried forward (LOCF) was applied.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (High-need)</title>
            <description>Adult participants with moderate to severe plaque psoriasis who were either not controlled by, or were intolerant to or had contraindications to at least two currently available systemic therapies (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept). Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.</description>
          </group>
          <group group_id="O2">
            <title>Group II (Low-need)</title>
            <description>Adult participants with moderate to severe plaque psoriasis who had undergone pretreatment with no more than one currently available systemic therapy (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept). Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Achieving a Greater Than or Equal to 75% Improvement in Psoriasis Area and Severity Index (PASI75) Score</title>
          <description>PASI75 response is defined as participants who achieved at least a 75% improvement in PASI score from Baseline to Week 22. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their responses to therapy. The PASI produces a numeric score that can range from 0 to 72 (the higher the number, the worse the disease).</description>
          <population>Per Protocol Population - All participants in the intent to treat population who completed the study without major protocol violations. For missing data, the last observation carried forward (LOCF) was applied.</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.739"/>
                    <measurement group_id="O2" value="0.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1 (High-need)</title>
        </group>
        <group group_id="E2">
          <title>Group 2 (Low-need)</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>SUDDEN HEARING LOSS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BLINDNESS UNILATERAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>VITREOUS DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DUODENITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>INFUSION RELATED REACTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>SUDDEN CARDIAC DEATH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>SERUM SICKNESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>SKIN INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>STERNAL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>WHIPLASH INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>PSORIATIC ARTHROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>LYMPHANGIOSIS CARCINOMATOSA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>MALIGNANT PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>METASTATIC RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>OVARIAN CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>EPIDIDYMITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS ATOPIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>PRURITUS GENERALISED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>BURSA REMOVAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>URETHRAL OPERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>SHOCK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="297"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="35" subjects_affected="30" subjects_at_risk="297"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="25" subjects_affected="20" subjects_at_risk="297"/>
                <counts group_id="E2" events="20" subjects_affected="12" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees not to pubish or publicly present any interim results of the study without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including, without limitation, slides and texts of oral or other public presentations and texts of any transmission through any elecontronic media) that report any results of study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

